UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **November 3, 2022**

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of incorporation)

001-35023	**26-2797813**
(Commission File Number)	*(IRS Employer Identification No.)*

8800 HSC Parkway
Bryan, Texas 77807
(Address of principal executive offices and zip code)

(979) 446-0027
(Registrant's telephone number including area code)

N/A
(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

iBio, Inc. (the "Company") has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 is furnished with this Current Report on Form 8-K.

Exhibit Number	Exhibit Description
99.1	Corporate Presentation of iBio, Inc. dated November 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2022

IBIO, INC.

By: /s/ Thomas F. Isett
Name: Thomas F. Isett
Title: Chief Executive Officer

AI-Powered Precision Antibody Therapeutics

November 2022

Forward-looking statements

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this presentation. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to obtain regulatory approvals for commercialization of its product candidates, including IBIO-101, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Company's most recent Annual Report on Form 10-K and the Company's subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this presentation is provided only as of today, and we undertake no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

The high failure rate of targets derived from traditional drug discovery methods contribute to the high cost of developing new therapies



Industry Benchmarks to Reach IND[1]

Failure Rate
>99%

Time
>3 Years

Cost
>$20-60M[2]

[1]https://www.researchgate.net/publication/265288848_The_Global_Biomedical_Industry_Preserving_US_Leadership; 2 Morgan et al, Nature Reviews Drug Discovery 2018

Antibody engineering is hard: drug programs often fail due to the inability of molecules to selectively bind to disease-causing cells vs. healthy ones

Antibodies are built from stretches of amino acids, which are the words and sentences that make up the natural language of biology. ***We are using AI to decipher that language with a goal to create immunotherapies directed toward hard-to-drug targets.***

- AI-powered precision-targeting
- Greater potency
- Enabling next-gen formats



Leveraging AI-powered discovery engine to develop precision antibody candidates against hard-to-drug targets

AI-powered *RubrYc*® Discovery Engine

Growing pipeline with immuno-oncology focus

Pipeline against hard-to-drug targets

- T_{reg} depleting anti-CD25 Tumor-selective EGFRvIII
- Targeted CCR8 mAb
- PD-1 agonist

Execution

- Added 6 pipeline candidates in first 6 months
- Platform capability advancing
- Successful advancement of 3 assets in last 3 months

Our AI-driven *RubrYc*® Discovery Engine tech stack



The *RubrYc* Discovery Engine in action



Therapeutics pipeline growth and maturation driven primarily by cancer immunotherapies developed with the *RubrYc* Discovery Engine



Our AI platform powers a focused, capital efficient business plan

Proprietary pipeline

- Advancing a select few "fast followers"
- Licensing and asset sales for other molecules

Discovery partnerships

- Partner existing molecules or discovery projects against new targets
- Potential for upfront, milestone payments and/or royalties


iBio
IBIO-101
IL-2 sparing anti-CD25
10

IBIO-101 for regulatory T-cell (T_{reg}) depletion

Target mechanism

Depletion of immunosuppressive T_{regs} via antibody dependent cellular cytotoxicity (ADCC), without disrupting activation of effector T-cells (T_{effs}) in the tumor microenvironment

Potential indications

- Solid tumors
- Hairy cell leukemia
- Relapsed mult. myeloma
- Lymphoma
- Head & neck cancer

Differentiation / opportunity

- IL-2 sparing anti-CD25 antibodies enables depletion of T_{regs} without affecting T_{effs}
- Fast-follower to the one other similar molecule in the clinic

Recent transactions

***Roche / Tusk Therapeutics (*Sep, 2018*)**
$81M upfront,
$758M total deal value

IBIO-101 reduces tumor growth by selectively depleting immuno-suppressive T_{regs} without affecting cancer killing T_{effs}



1st gen CD25 mAbs depleted immuno-suppressive T_{reg} and immuno-stimulatory T_{eff}

Limited efficacy

2nd gen RTX-003 selectively targets T_{regs} without blocking IL-2 signaling to T_{effs}

Strong preclinical anti-tumor response

[1]Data on file. Treg = Regulatory T Cells; Teff = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity

IBIO-101 selectively depletes T_{regs}

iBio-101 potently binds recombinant CD25 | while preserving IL-2 signaling | which leads to T_{reg} depletion | while sparing T_{effs}



- Negative control, EC_{50} = no binding
- IBIO-101, EC_{50}= 16.4 ng/ml
- RG6292 (Roche), EC_{50}= 24.7 ng/ml
- IL2, EC_{50}= 0.11 ng/ml
- IBIO-101, EC_{50}= 0.17 ng/ml
- RG6292, EC_{50} = 0.14 ng/ml
- Negative control, EC_{50} = no cell killing
- IBIO-101, EC_{50}= 4.7 ng/ml
- RG6292, EC_{50} = 18.6 ng/ml
- T_{reg} killing, EC_{50}= 7.09 ng/ml
- Activated $CD4^+$ T_{eff} killing, EC_{50}= no activity
- Activated $CD8^+$ T_{eff} killing, EC_{50}= no activity

IBIO-101 increases in T_{eff}/T_{reg} ratio, inhibiting tumor growth

Potently increases T-eff/T-reg ratio[1]



Tumor growth inhibition correlates with T-eff/T-reg ratio



IBIO-101 in combination with a checkpoint inhibitor shows greater efficacy

IBIO-101 + PD-1 Checkpoint Inhibitor
Enhances Tumor Suppression




iBio
Anti-EGFRvIII
High ADCC mAb against
tumor-specific EGFRvIII cells
16

EGFRvIII for glioblastoma and other cancers

Target mechanism

Binding a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC.

EGFRvIII is constantly "switched on" which can lead to the development of a range of different cancers.

Potential indications

- Glioblastoma
- Head & neck cancer
- Non-small cell lung cancer

Differentiation / opportunity

Novel EGFRvIII program utilizing an ADCC mechanism, potentially further reducing toxicity & expanding therapeutic window

Recent transactions

1223 (EGFR program), plus additional projects using Lava's platform.

*Seagen transaction with LAVA Therapeutics was an exclusive license to LAVA-

**Taiho transac tion to acquire Cullinan Oncology's subsidiary, Cullinan Pearl, which has worldw ide rights outside of Japan to CLN-081/TAS6417 (EGFR mut ant

iBio's Anti-EGFRvIII mAbs selectively kill EGFRvIII-positive tumor cells and not EGFR1-expressing cells in healthy tissues



iBio's EGFRvIII-selective mAbs kill tumor cells without affecting healthy cells

iBio EGFRvIII mAbs bind recombinant EGFRvIII



which leads to tumor cell killing



but not binding wild-type EGFR1



and thus not affecting healthy cells



- Negative control, EC_{50} = no binding
- Celuximab, EC_{50} = 0.018 nM
- SD-233883, EC_{50} = 0.008 nM
- SD-710726, EC_{50} = 0.020 nM

iBio


iBio
Anti-CCR8
Highly ADCC anti-CCR8 for the depletion of T-regulatory cells
20

CCR8 for tumor-infiltrating T_{reg} depletion

Target mechanism

Tumor-infiltrating Tregs highly express CCR8. iBio program targets depletion of highly immunosuppressive CCR8+ Tregs in tumor microenvironment via an ADCC mechanism

Potential indications

- Broadly applicable in solid tumors
- Prospective combination therapy

Differentiation / opportunity

- Selective binding to CCR8 over its closely related cousin, CCR4

Recent transactions

*Fibrogen / HiFiBio (Jun. & Dec. 2021): $25M option fee, $35M option exercise, $1.1B milestones

**Gilead / Jounce (Sep. 2020): $85M upfront, $35M equity investment, $685 clinical, regulatory and commercial milestones

*Fibrogen / HiFiBio: Fibrogen purchased option to multiple programs in June 2021, then exercised the option for excl. license to CCR8 program in Dec. 2021.
**Gilead / Jounce: Exclusive worldwide license to anti-CCR8 antibody.

CCR8+ T_{reg} cells are tumor infiltrating and highly immunosuppressive

Depletion of CCR8+ Treg cells has potential to evoke potent tumor immunity



CCR8 antibodies have high-specificity binding and ADCC cell killing

High Specificity CCR8 Cell Binding



iBio antibody + target cell	CCR8 Cells Negative Controls
CCR8	Secondary antibody
CCR4	No antibody

High Specificity & Potent Cell Killing
(no ADCC enhanced Fc engineering)



iBio antibody + target cell	
	CCR8
	CCR4


iBio
PD-1 agonist
Supports restoration of homeostasis for inflammatory diseases
24

PD-1 Agonist for treatment of inflammatory disorders while preserving low inflammation state in healthy tissue

Target mechanism

- Selectively binds PD-1 without PD-L1/PD-L2 blocking
- Agonizes PD-1 to suppress of auto-reactive T-cells

Potential indications

- Inflammatory bowel disease
- Systemic lupus erythematosus
- Multiple sclerosis

Differentiation / opportunity

- Greater safety agonist antibodies known for off-target effects
- Leverage AI discovery engine to compete among a small number of players

Recent transactions



*Gilead / Mirobo: Mirobio's lead assets were two checkpoint agonists for autoimmune diseases; most advanced had entered phase 1
**Merck / Pandion: Merch acquired company, including multiple autoimmune assets, lead had completed phase 1a safety study. Preclinical PD-1 agonist was in Pandion pipeline

Antagonizing PD-1 with PD-L1 blocking worsens autoimmunity and systemic inflammation



Agonizing PD-1 without blocking PD-L1 restores activated T-cell suppression



Autoimmunity

Improved

Healthy Tissue
Low-inflammation preserved

Diseased Tissue
Reduced inflammation

In vitro PD-1 agonism equals or surpasses benchmarks and PD-L1



Ab ID	EC50 (nM)
SD-671823	0.88
SD-300670	0.31
SD-030629	0.36
SD-136366	0.28
SD-759028	0.52
SD-313018 (bispecific)	0.30
AnaptysBio APE12095	17.4
BMS/Celgene PD1AB6	0.76
IgG1 isotype control	inactive

Primary T-cell suppression equals or surpasses benchmarks and PD-L1




iBio
In summary
30

Strong and growing IP estate provides exclusivity for iBio's pipeline

Patent protection includes:

- Intellectual property (IP) around iBio's biopharmaceutical candidates
- IP related to the ***RubrYc***® Discovery Engine (including Notice of Allowance from USPTO)

Our leadership team brings drug development & bioprocessing experience

Tom Isett
CEO

- GE
- Lonza
- BD
- commence bio
- i.e. Advising

Martin Brenner, DVM, Ph.D.
CSO

- PFENEX
- AstraZeneca
- Lilly
- MERCK
- Pfizer

Robert Lutz, MBA
CFBO

- STRONGBRIDGE BIOPHARMA
- Shire
- Goldman Sachs

Marc Banjak
GC

- istari ONCOLOGY
- Dova PHARMACEUTICALS
- ICON
- B BRAUN SHARING EXPERTISE
- PPD

Lisa Middlebrook
CHRO

- LUPIN
- Lonza

iBio: Summary

Pipeline of difficult to find biologics

- Pipeline of 10 preclinical primarily immuno-oncology (I/O) biologics
- Targets have been of interest to major I/O companies
- Lead asset is a next-generation anti-CD25 (fast follower to Roche's RG6292)
- Expected to file IND no later than H1 2024

AI-driven discovery platform technology

- Own patent-protected platform which uses artificial intelligence engine and proprietary antibody library to discover antibodies that others can't easily find

Preclinical development capability

- Preclinical team with a history of quickly and efficiently moving candidates to the clinic
- Built >10-product pipeline in 18 months

Financial

- Ticker: IBIO (NYSE-A); ~9M shares outstanding
- In process of selling CDMO facility and business to potentially provide funding for I/O pipeline and platform
- Reduced SG&A spend post sale of CDMO; expecting run rate of $2.5-$3.0M per month (~50% of prior rate)
- $39.5M of cash/cash equivalents as of 6/30/22